HLS Therapeutics (HLS) Stock Price, News & Analysis

Company Overview

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.

Key Stats

• Today's Range: C$4.33 to C$4.43
• 50-Day Range: C$3.92 to C$4.75
• 52-Week Range: C$3.00 to C$4.98
• Volume: 14,000 shs
• Average Volume: 14,714 shs
• Market Capitalization: C$97.89 million
• P/E Ratio: N/A
• Dividend Yield: 4.55%
• Price Target: C$4.50
• Consensus Rating: Hold

HLS Stock Analysis - Frequently Asked Questions

How have HLS shares performed this year?

HLS Therapeutics' stock was trading at C$3.93 at the start of the year. Since then, HLS shares have increased by 12.0% and is now trading at C$4.40.
View the best growth stocks for 2025 here.

How were HLS Therapeutics' earnings last quarter?

HLS Therapeutics Inc. (TSE:HLS) issued its earnings results on Thursday, November, 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. HLS Therapeutics had a negative trailing twelve-month return on equity of 25.27% and a negative net margin of 38.70%.
Read the conference call transcript.

How do I buy shares of HLS Therapeutics?

Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of HLS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HLS Therapeutics investors own include Toronto-Dominion Bank (TD), Meta Platforms (META), NVIDIA (NVDA), CohBar (CWBR), Alphabet (GOOG), Great-West Lifeco (GWO) and ObsEva (OBSV).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 5/02/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:HLS
• CIK: N/A
• Web: www.hlstherapeutics.com
• Phone: 647-495-9000
• Fax: N/A
• Employees: 91
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$4.50
• High Stock Price Target: C$5.00
• Low Stock Price Target: C$4.00
• Potential Upside/Downside: +2.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-15,528,530.76
• Net Margins: -38.70%
• Pretax Margin: N/A
• Return on Equity: -25.27%
• Return on Assets: -2.89%

Debt

• Debt-to-Equity Ratio: 86.50
• Current Ratio: 1.56
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: C$40.13 million
• Price / Sales: 2.44
• Cash Flow: C$0.29 per share
• Price / Cash Flow: 15.22
• Book Value: C$2.51 per share
• Price / Book: 1.75

Miscellaneous

• Outstanding Shares: 22,247,717
• Free Float: N/A
• Market Cap: C$97.89 million
• Optionable: Not Optionable
• Beta: 1.07